Project Grant R01DA062720
Award Date
6/15/25
Completion Date
2/28/29
Dollars Obligated
$703K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 "Drug Use and Addiction Research Programs," provides $400,000 in funding to Iontx Inc. to advance the development of a novel small-molecule compound that modulates the FGF13/NAV1.6 protein complex to normalize nucleus accumbens activity for the treatment of Cocaine Use Disorder (CUD). The primary objectives are to conduct structure-activity relationship (SAR) analysis and optimization...
This $1,476,750 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a pilot randomized controlled trial to evaluate the use of the medication semaglutide as an adjunct to buprenorphine for the treatment of opioid use disorder (OUD). The research will be conducted by Brigham & Women's Hospital Inc., a prominent academic medical center in Boston, Massachusetts that is part of the Mass General Brigham...
This $1,447,919 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research into the development of cocaine addiction and interventions targeting the "need-state" hypothesis. The project aims to use an animal model to identify early markers of addiction vulnerability, measure associated neural activation patterns, and evaluate whether treatment with a GLP-1 receptor agonist can reverse these...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on investigating the role of striatal enkephalin in cocaine use disorder. The $226,295 award, provided to the University of Texas at Austin, aims to: Determine the necessity of striatal enkephalin in cocaine-induced adaptations in the striatopallidal circuit through electrophysiology recordings and neurochemical studies. Examine the...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $1,766,868 to The University of Texas at El Paso (UTEP) from September 15, 2024 through May 31, 2029. The project aims to validate a novel computational neurobiological model of drug-taking behavior in the face of cost, with a focus on the role of the striosomal circuitry of the dorsomedial striatum. The research will utilize electrophysiology,...
This $405,230 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to advance NR4A1 as a novel target for the treatment of cocaine use disorder. The award period runs from January 15, 2025 to December 31, 2025. The key products and services to be delivered through this funding include: 1) Lead identification through synthesis and screening of cytosporone B (CSNB) derivatives that activate human and mouse...
This $492,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports a multidimensional investigation into the genetic and epigenetic factors underlying cocaine addiction. The University of Chicago, the awardee, will conduct high-resolution chromatin accessibility and DNA methylation profiling to delineate cell-type and circuit-specific epigenetic configurations following cocaine self-administration in...
The National Institute on Drug Abuse (NIDA) awarded Oregon Health & Science University (OHSU) a $234,000 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to investigate the mechanisms supporting cue-induced cocaine craving. The project will use translating ribosome affinity purification and RNA sequencing (TRAP-seq) to identify mRNAs that are actively translated in nucleus accumbens neurons of rats during re-exposure to a cocaine-associated cue after a period of...
This $856,625 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), supports an exploratory randomized controlled trial (RCT) of the effects of oral semaglutide on alcohol craving and consumption. The University of Colorado-Denver, as the prime awardee, will conduct this 2-year study to assess the safety, tolerability, and efficacy of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, compared to placebo...
This $1,742,971 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research to investigate the epigenetic regulation of HIV/SIV and cocaine-induced inflammasome activation, and the potential therapeutic benefits of combining cannabinoids with antiretroviral therapy. The key objectives are to: 1) Examine the epigenetic mechanisms underlying cannabinoid-mediated reduction of cocaine-induced...